[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Peking Union Medical College Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":629},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,314,0,25,[9,48,72,98,123,146,172,192,211,238,264,293,322,347,371,391,422,440,460,485,505,531,554,584,603],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645135","phase-2-a-phase-ii-study-of-adjuvant-durvalumab-combined-with-gemoxgc-chemotherapy-followed-by-lenvatinib-versus-capecitabine-in-biliary-tract-cancer-100645135",false,"NCT07679399","A Phase II Study of Adjuvant Durvalumab Combined With GEMOX\u002FGC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.","A Randomized, Open-label, Phase II Clinical Study of Durvalumab Combined With GEMOX\u002FGC Chemotherapy Followed by Lenvatinib Versus Capecitabine as Adjuvant Therapy for Biliary Tract Cancer.","Inclusion Criteria:\n\n1. The subjects voluntarily participated in the study and agreed to sign the written informed consent. They had good compliance and cooperated with the follow-up.\n2. When signing the informed consent form, one must be at least 18 years old and no older than 75 years old, and there is no restriction on gender.\n3. Histologically confirmed cholangiocarcinoma or gallbladder cancer (excluding pancreatic cancer or ampullary cancer)\n4. Having undergone radical surgical treatment (R0 or R1 resection)\n5. The ECOG score is between 0 and 1\n6. The hematology and organ functions are adequate. Based on the following laboratory test results obtained within 14 days prior to the start of the treatment (unless otherwise specified)\n7. Blood routine test: (Within 14 days before screening, no blood transfusion, no use of G-CSF, and no use of drugs for correction) Hb ≥ 90 g\u002FL; Neutrophils ≥ 1.5 × 10\\^9\u002FL; PLT ≥100×10\\^9\u002FL\n8. Biochemical test: (No albumin transfusion within 14 days)\n9. Appropriate liver function: ALT and AST ≤ 2.5 × ULN; serum bilirubin ≤ 2.0 × normal upper limit (ULN); these conditions do not apply to patients with confirmed Gilbert syndrome. Any clinically significant biliary obstruction should be relieved before enrollment. Albumin ≥ 2.8 g\u002FdL. Appropriate renal function: creatinine ≤ 1.5 × ULN, or creatinine clearance rate (CCr) \\> 50 mL\u002Fmin (calculated using the standard Cockcroft-Gault formula)\n10. Coagulation function: International Normalized Ratio (INR) ≤ 1.5\n11. Fertile women: Agree to abstain from sexual intercourse (avoiding heterosexual intercourse) or use a contraceptive method with a failure rate of less than 1% during the treatment period and for at least 6 months after the last administration. If the female patient has menstruated, has not reached post-menopausal status (continuous absence of menstruation for ≥ 12 months, no other causes found apart from menopause), and has not undergone sterilization surgery (removal of ovaries and\u002For uterus), then it is considered that the patient is fertile. Examples of contraceptive methods with a failure rate of less than 1% include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormonal release intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated relative to the duration of the clinical trial and the patient's preferred lifestyle and daily routine. Periodic abstinence (such as calendar days, ovulation period, symptom-based body temperature, or post-ovulation methods) and withdrawal from sexual intercourse are unacceptable contraceptive methods.\n12. Male: Agree to abstinence (not engaging in heterosexual sexual intercourse) or use of contraceptive measures, agree not to donate sperm, defined as follows: When the female partner has reproductive capacity, the male patient must abstain from sexual activity during the treatment period and for 6 months after the last administration, or use condoms and other contraceptive methods to ensure a contraceptive failure rate of less than 1% per year. During the same period, the male patient must also agree not to donate sperm. When the female partner is pregnant, the male patient must abstain from sexual activity or use condoms for contraception during the treatment period and for 6 months after the last administration, to avoid any impact on the fetus. The reliability of sexual abstinence should be evaluated relative to the duration of the clinical trial and the patient's preferred lifestyle and daily routine. Periodic abstinence (such as calendar days, ovulation period, symptom-based body temperature or after ovulation methods) and withdrawal from sexual intercourse are unacceptable contraceptive methods.\n\nExclusion Criteria:\n\n1. Pancreatic cancer or ampullary cancer\n2. Not yet fully recovered from the surgery or with unremoved bile duct obstruction\n3. Pregnant women (with a positive pregnancy test before taking the medicine) or lactating women\n4. Having had other untreated malignant tumors in the past (within the last 5 years) or simultaneously, excluding cured skin basal cell carcinoma, skin squamous cell carcinoma, in situ breast cancer and in situ cervical cancer, treated superficial bladder cancer, and prostate adenocarcinoma that underwent surgical treatment and whose PSA tumor marker was within the normal range.\n5. Who has previously received immunotherapy or chemotherapy\n6. Serious coexisting diseases that may interfere with the treatment of the proposed plan, including potential severe infections\n7. There is drug abuse; or any medical, psychological or social condition that may affect the research, the patient's compliance, be unstable, or even potentially endanger the patient's safety.\n8. Significant clinical cardiovascular and cerebrovascular diseases, including but not limited to acute myocardial infarction occurring within 6 months prior to enrollment, severe\u002Funstable angina pectoris, cerebrovascular accident or transient cerebral ischemic attack, congestive heart failure (NYHA classification ≥ 2 grade); arrhythmias requiring anti-arrhythmic drugs (except beta-blockers or digoxin); repeated electrocardiogram QTc interval \\> 480 milliseconds (ms)\n9. Presence of persistent infection of grade 2 or above (CTCAE 5.0)\n10. Having a history of thromboembolic events within the past 6 months (including stroke and\u002For transient ischemic attack)\n11. Hypertension that has not been well controlled by antihypertensive drugs (systolic blood pressure \\> 160 mmHg, diastolic blood pressure \\> 100 mmHg)\n12. Participants who had active autoimmune diseases or autoimmune disease history in the past two years; those with active, known, or suspected autoimmune diseases that may affect important organ functions or that may require systemic immunosuppressive therapy, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, antiphospholipid syndrome related to vascular thrombosis, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis or glomerulonephritis. However, type 1 diabetes, hypothyroidism requiring only hormone replacement, skin diseases that do not require systemic treatment (such as vitiligo, psoriasis or alopecia) or participants who will not have a recurrence without external triggering factors are allowed. Alternative therapies (such as thyroid hormone, insulin or physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) are not considered as a form of systemic treatment.\n13. A known history of active tuberculosis (with the tuberculosis bacteria)\n14. Those who have a history of gastrointestinal bleeding within the past 6 months or have a clear tendency towards gastrointestinal bleeding, such as esophageal varices with bleeding risk, active gastrointestinal ulcer lesions, or fecal occult blood ≥ (++), are not eligible for enrollment; those with evidence or history of ≥ 3 grade (CTCAE 5.0) bleeding events due to bleeding mechanism disorders are also excluded.\n15. Severe non-healing wounds, ulcers or fractures\n16. There are unresolved toxicities of grade \\> 1 that were caused by any previous treatment\u002Foperation (CTCAE 5.0, except for hair loss, anemia, and hypothyroidism)\n17. Patients who have objective evidence of severe lung function impairment in the past and at present, such as a history of severe pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, or drug-related pneumonia\n18. After the researchers' comprehensive assessment of the patient's condition, it was determined that the patient was not suitable for participating in this study.\n19. At the same time, he\u002Fshe was also involved in another clinical study.","ALL","18 Years","75 Years",{"count":21,"type":22},222,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study is designed as a prospective, randomized, open-label, phase II clinical trial to systematically evaluate the efficacy and safety of durvalumab combined with GEMOX\u002FGC chemotherapy followed by lenvatinib, compared with capecitabine monotherapy, as adjuvant therapy for biliary tract cancer (BTC) after curative-intent resection.The primary objective is to determine whether the combination regimen can significantly improve the 1-year recurrence-free survival (RFS) rate. Secondary objectives include assessment of overall survival (OS) and the incidence of treatment-related adverse events. The overall aim is to identify a more effective and safer treatment strategy for postoperative adjuvant therapy in BTC.",[28],"Biliary Tract Neoplasms Immunotherapy",[30,31,32,33,34],"Biliary Tract Cancer","durvalumab","lenvatinib","capecitabine","adjuvant therapy","RECRUITING","2026-06-30",{"date":38,"type":39},"2026-07-01","ACTUAL",{"date":41,"type":39},"2025-06-01",{"date":43,"type":22},"2027-06-01",{"name":45,"class":46},"Peking Union Medical College Hospital","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100616550","real-time-algorithm-driven-ventilation-feedback-to-improve-lung-protective-ventilation-in-patients-with-ards-realvent-study-100616550","NCT07307066","Real-Time Algorithm-Driven Ventilation Feedback to Improve Lung-Protective Ventilation in Patients With ARDS (REALVENT-study)","REALVENT","Inclusion Criteria:\n\n* Age between 18 and 75 years\n* Receiving invasive mechanical ventilation via endotracheal intubation at the time of screening\n* Initiation of invasive mechanical ventilation within the past 24 hours\n* PaO₂\u002FFiO₂ ≤ 200 mmHg on PEEP ≥ 8 cmH₂O or, if arterial blood gas is unavailable: SpO₂\u002FFiO₂ ≤ 235 with SpO₂ ≤ 97%\n* Chest imaging (chest X-ray or CT) showing bilateral pulmonary infiltrates not fully explained by pleural effusions, lobar collapse, or pulmonary nodules\n* Respiratory failure not fully explained by cardiac failure or fluid overload\n* Expected to require invasive mechanical ventilation for ≥ 72 hours after enrollment\n\nExclusion Criteria:\n\n* Receipt of extracorporeal membrane oxygenation (ECMO) or high-frequency oscillatory ventilation at screening\n* Brain death or anticipated withdrawal of life-sustaining treatment within 72 hours\n* Pregnancy\n* Known neuromuscular disease affecting spontaneous respiratory effort\n* Prisoners or individuals unable to provide informed consent or surrogate consent\n* Simultaneous enrollment in another interventional ICU study\n* Lack of digital infrastructure for real-time ventilator waveform acquisition",{"count":56,"type":22},208,[58],"NA","The REALVENT trial is designed to evaluate whether a real-time, algorithm-driven ventilation feedback strategy can improve lung-protective ventilation (LPV) achievement rates in critically ill patients receiving invasive mechanical ventilation. This multicentre randomised controlled trial will compare real-time respiratory waveform monitoring with automated feedback against standard ICU care. The primary endpoint is the LPV achievement rate over the first 72 hours.",[61,62,63,64],"ARDS (Acute Respiratory Distress Syndrome)","VILI (Ventilator-induced Lung Injury)","Respiratory Failure","Critical Illness","2026-06-29",{"date":38,"type":39},{"date":68,"type":39},"2025-12-30",{"date":70,"type":22},"2027-02-28",{"name":45,"class":46},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":47},"100644567","phase-2-phase-ii-study-of-trastuzumab-rezetecan-combined-with-adebrelimab-and-lenvatinib-as-first-line-therapy-for-advanced-her2-positiveher2-low-biliary-tract-cancer-100644567","NCT07670273","Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive\u002FHER2-Low Biliary Tract Cancer","A Prospective, Open-label, Multicenter Phase II Clinical Study of Rikang Trastuzumab in Combination With Adebrelimab and Lenvatinib for First-line Treatment of HER2-positive or Low-expressing Locally Advanced or Metastatic Biliary Tract Cancer","Inclusion Criteria:\n\n1. The HER2-positive subjects voluntarily participated in the study and agreed to sign the written informed consent form, and they had good compliance.\n2. Age ≥ 18 years old, gender not limited;\n3. Locally advanced or metastatic cholangiocarcinoma, including cholangiocarcinoma (intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma) and gallbladder cancer, which has been confirmed by pathological histology or cytology;\n4. Not suitable for radical surgical resection or local treatment. Subjects who have not received any systemic anti-tumor therapy in the past; allowed to have received radical treatment previously (including surgical treatment and postoperative adjuvant chemotherapy and\u002For radiotherapy), and the interval from the last administration of radical treatment to disease recurrence is at least 6 months, and no systemic anti-tumor treatment was received during the recurrence or metastasis stage.\n5. HER2 positive (IHC 3+ or IHC 2+ and FISH detects HER2\u002FCEP17 ≥ 2.0), HER2 low expression (IHC 2+\u002FFISH- or IHC 1+);\n6. There is at least one measurable lesion that meets the requirements of RECIST v1.1.\n7. The ECOG score is between 0 and 1.\n8. Expected survival period ≥ 12 weeks;\n9. The organs and bone marrow have sufficient functions and meet the following requirements: (within 14 days before starting the treatment) 1) Blood routine examination: (within 14 days before the screening, no blood transfusion, no use of granulocyte colony-stimulating factor \\[G-CSF\\], no use of drugs to correct): A. Hemoglobin (Hb) ≥ 90 g\u002FL; B. Neutrophil count (ANC) ≥ 1.5 × 109\u002FL; C. Platelet count (PLT) ≥ 75 × 109\u002FL; 2) Blood biochemical examination should meet the following standards (no albumin transfusion within 14 days before the screening): A. Serum total bilirubin \\[BIL\\] ≤ 2xULN (for Gibert syndrome patients, ≤ 3xULN); B. Alanine aminotransferase \\[ALT\\] and aspartate aminotransferase \\[AST\\] ≤ 3.0xULN; C. For patients with liver metastasis, ALT and AST should be ≤ 5xULN; Serum creatinine (Cr) ≤ 1.5xULN or endogenous creatinine clearance rate ≥ 50 ml\u002Fmin (Cockcroft-Gault formula): Male: Cr clearance rate = ((140 - age) × weight) \u002F (72 × blood Cr); Female: Cr clearance rate = ((140 - age) × weight) \u002F (72 × blood Cr) × 0.85 (weight unit: kg; blood Cr unit: mg\u002FmL)\n10. For both male subjects with fertile partners and female subjects with fertile partners, they must take effective contraceptive measures from the moment they sign the informed consent form until 7 months after the last administration of the test drug. During the same period, male subjects must agree not to donate sperm, and female subjects must agree not to donate eggs. For female subjects with fertility, the serum HCG test must be negative within 7 days before the first administration of the drug, and they must be in the non-breastfeeding period.\n\nExclusion Criteria:\n\n1. Histological or cytological pathology confirmed that the bile duct tumors were of non-adenocarcinoma pathological types such as ampullary carcinoma, small cell carcinoma, neuroendocrine tumor, sarcoma, mucinous cystic tumor, etc.\n2. Having another active malignant tumor within 5 years or simultaneously; excluding cervical carcinoma in situ that has been fully treated, as well as basal cell or squamous cell carcinomas of the skin.\n3. Participants who have previously received immunotherapy, HER2-targeted, or ADC drug treatment, including immune checkpoint inhibitors (such as anti-PD-1\u002FL1 antibodies, anti-CTLA-4 antibodies, anti-TIGIT antibodies, anti-LAG3 antibodies, etc.), immune checkpoint agonists (such as CD40, CD137, OX40 antibodies, etc.), and any other treatments targeting the immune mechanism of tumor treatment;\n4. The adverse reactions from previous anti-tumor treatments have not yet recovered to a NCI-CTCAE v5.0 rating of ≤ 1 (excluding cases of hair loss, meeting the numerical requirements of the inclusion criteria, or other situations determined by the investigator not to affect the treatment with the study drug).\n5. Any disease evidence determined by the researchers (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, moderate or severe ascites with clinical symptoms; uncontrollable or moderate to large amounts of pleural effusion, pericardial effusion, accompanied by acute or chronic uncontrolled pancreatitis, active bleeding disorders, active infections, active ILD\u002Finterstitial lung disease, severe chronic gastrointestinal diseases related to diarrhea, mental disorders\u002Fsocioeconomic conditions) or the history of allogeneic organ or syngeneic bone marrow transplantation that the researchers consider makes the subject unsuitable for participation in the study or affects the compliance with the study protocol;\n6. History of severe cardiovascular and cerebrovascular diseases: Within 12 months prior to randomization, there were manifestations of NYHA \"grade 3 or above\" congestive heart failure, unstable angina pectoris, myocardial infarction, poorly controlled arrhythmia or cerebral hemorrhage; cardiac echocardiography showed left ventricular ejection fraction (LVEF) \\\u003C 50%; corrected QT interval (QTe) \\> 480ms (calculated using the Fredericia method; if QTc is abnormal, it can be continuously detected for 3 times at intervals of 2 minutes, and the average value is taken); poorly controlled hypertension (systolic blood pressure ≥ 150 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg, based on the average value obtained from ≥ 2 measurements); previous occurrence of hypertensive crisis or hypertensive encephalopathy.\n7. The subjects have congenital or acquired immune system deficiencies (such as HIV-infected individuals); or have a history of organ transplantation;\n8. Those who had active tuberculosis within one year prior to enrollment, or those who had a history of active tuberculosis infection more than one year ago but did not receive proper treatment.\n9. The study excluded those who had a history of gastrointestinal bleeding within 6 months prior to treatment or who had a clear tendency towards gastrointestinal bleeding; those with known hereditary or acquired bleeding disorders (such as coagulation dysfunction) or thrombosis tendencies;\n10. Within 4 weeks prior to the start of the treatment, if one has undergone major surgical procedures (except for biopsy procedures); if the surgical incision has not fully healed; if major surgical treatment is expected to be required during the study period; if a minor traumatic surgical procedure (such as biopsy procedures) was performed within 7 days prior to the start of the treatment.\n11. Severe, non-healed or open wounds, active ulcers or untreated fractures;\n12. Previous or current presence of central nervous system metastasis;\n13. The first study requires that the subjects use attenuated live vaccines within 28 days before the start of the treatment, or that they are expected to use attenuated live vaccines during the study treatment period or within 60 days after the last administration of the study drug.\n14. Patients with active autoimmune diseases, or those with a history of autoimmune diseases and who require long-term use of systemic glucocorticoids (equivalent dose of prednisone ≥ 10 mg\u002Fday, for more than 2 weeks) or immunosuppressants.\n15. Based on the researchers' assessment, there are other factors that might have affected the research results or led to the premature termination of this study, such as alcohol abuse, drug abuse, having other serious diseases (including mental illnesses) that require combined treatment, severely abnormal laboratory test values, family or social factors, and other situations that might have affected the safety of the subjects or the collection of trial data.",{"count":80,"type":22},70,[25],"This phase II study evaluates the efficacy and safety of Trastuzumab Rezetecan in combination with Adebrelimab and Lenvatinib as first-line therapy for patients with locally advanced or metastatic HER2-positive or HER2-low biliary tract cancer. The primary objective is the objective response rate (ORR). Key secondary objectives include efficacy endpoints-progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and duration of response (DoR)-and safety assessments comprising adverse events (AEs), serious adverse events (SAEs), vital signs, and laboratory findings.",[28],[30,85,86,87,88,89],"Immune Checkpoint Inhibitors","Trastuzumab Rezetecan","Adebrelimab","Lenvatinib","HER2-Positive\u002FLow-Expression","2026-06-25",{"date":92,"type":39},"2026-06-26",{"date":94,"type":39},"2026-04-29",{"date":96,"type":22},"2028-04-29",{"name":45,"class":46},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":105,"targetDuration":107,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":113,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":47},"100644523","spatial-multi-omics-and-intelligent-early-warning-of-pancreatic-cancer-cachexia-100644523","NCT07670286","Spatial Multi-omics and Intelligent Early Warning of Pancreatic Cancer Cachexia","Spatial Multi-omics Mechanism Analysis and Multimodal Intelligent Early Warning of Cachexia in Pancreatic Cancer","Inclusion Criteria:\n\n* Patients with pathologically confirmed pancreatic ductal adenocarcinoma.\n* Aged ≥18 years with an expected survival time of ≥1 month (to be assessed for the advanced cohort). Assessment criteria: Comprehensive evaluation based on the patient's radiological tumor burden, vital organ function and physical status. Specific quantitative indicators: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2, or Karnofsky Performance Status (KPS) score of ≥60. For patients in the advanced cohort, the assessment shall be jointly confirmed by two attending physicians with the professional title of associate chief physician or above in combination with radiological examination results.\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Complicated with other untreated malignant tumors or severe mental disorders.\n* Pregnant women or patients unable to cooperate with follow-up.",{"count":106,"type":22},500,"1 Year","OBSERVATIONAL","The goal of this observational study is to explore the spatial multi-omics mechanism of cachexia in pancreatic cancer and construct a high-precision multimodal intelligent early warning model for its early diagnosis in pathologically confirmed pancreatic ductal adenocarcinoma patients aged ≥18 years with an expected survival of ≥1 month.\n\nThe main questions it aims to answer are: 1) Can spatial transcriptomics\u002Fmetabolomics reveal the interaction mechanism between tumor microenvironment and metabolism in pancreatic cancer cachexia? 2)Can a multimodal AI early warning model be built to achieve accurate early identification of pancreatic cancer cachexia? Researchers will compare the surgical cohort and advanced cohort to see the differences in cachexia incidence and progression rules among different subgroups. Participants will complete baseline questionnaires on physical and mental state, nutrition and muscle strength, undergo imaging examinations and provide biological samples (blood, feces, tissue etc.), and receive regular follow-ups for updated questionnaires, imaging rechecks and supplementary biological sample collection until death, loss to follow-up or voluntary withdrawal.",[111,112],"Pancreatic Cancer","Cachexia; Cancer; Sarcopenia",[114,115,111,116],"Spatial Multi-omics","Multimodal intelligent","Cachexia",{"date":92,"type":39},{"date":119,"type":39},"2026-04-24",{"date":121,"type":22},"2028-08-31",{"name":45,"class":46},{"id":124,"slug":125,"hasResults":12,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":23,"phases":133,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":47},"100643962","phase-2-evaluation-of-the-efficacy-and-safety-of-compound-betamethasone-in-pulmonary-sarcoidosis-100643962","NCT07668895","Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis","A Prospective, Multi-center, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosed within the past 3 months with stage I-II (based on chest CT) treatment-naive pulmonary sarcoidosis, meeting the following: A. Histopathological diagnosis of sarcoidosis via tissue biopsy (bronchial mucosa, intrathoracic lymph nodes, lung, pleura, etc.) obtained during bronchoscopy; B. Chest HRCT showing mediastinal and hilar lymphadenopathy, with or without pulmonary infiltrates (nodules, patchy opacities, ground-glass opacities, etc.); C. CT stage confirmed independently by at least two experts in the field (among three experts reviewing the chest HRCT images).\n* Requiring systemic glucocorticoid therapy.\n* Able to complete scheduled follow-up visits.\n* Patient and family members understand the study protocol, are willing to participate in this study, and are able to provide written informed consent.\n\nExclusion Criteria:\n\n* Patient or family members are unable to understand the conditions and objectives of this study, or are unable to provide informed consent.\n* Subjects who cannot comply with the follow-up schedule as required by the protocol.\n* Presence of other serious diseases that, in the investigator's judgment, may affect patient safety or compliance.\n* Any significant clinical or laboratory abnormalities that, in the investigator's judgment, may affect safety evaluation.\n* Pregnant or breastfeeding women, or patients who cannot use effective contraception during the study period and within 3 months after the study ends.\n* Active malignancy requiring treatment (surgery, medical therapy, or radiotherapy).\n* Hypersensitivity to Diprospan (Compound Betamethasone) or prednisone.","100 Years",{"count":132,"type":22},126,[25,134],"PHASE3","The goal of this clinical trial is to learn whether a study drug called Compound Betamethasone (also known as Diprospan) works to treat pulmonary sarcoidosis in people with early-stage disease (stage I or II). It will also learn about its safety compared to the standard treatment, prednisone.\n\nThe main questions it aims to answer are:\n\n* How much does the study drug improve lung function (measured by a test called FVC%) after 24 weeks of treatment?\n* How does it compare to prednisone in controlling symptoms, reducing chest lymph node swelling, and preventing relapse? Researchers will compare Compound Betamethasone injections (given once every 4 weeks) to prednisone pills (taken daily with a gradual dose reduction).\n\nParticipants will:\n\n* Receive either the study drug injection or prednisone pills for 24 weeks\n* Visit the clinic for checkups and lung function tests at weeks 6, 12, and 24\n* Have chest CT scans and blood tests to monitor their condition and any side effects\n* Be followed up for additional 24 weeks (up to week 48) to see if the disease comes back after treatment stops",[137],"Sarcoidosis, Pulmonary","NOT_YET_RECRUITING","2026-06-21",{"date":90,"type":39},{"date":142,"type":22},"2026-07",{"date":144,"type":22},"2028-07",{"name":45,"class":46},{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":155,"conditions":156,"keywords":159,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},"100641942","risk-factor-assessment-for-acute-pulmonary-hypertension-crisis-100641942","NCT07653958","Risk Factor Assessment for Acute Pulmonary Hypertension Crisis","Research on the Clinical Risk Factor Assessment System for Acute Pulmonary Hypertension Crisis and Its Mortality","Inclusion Criteria:\n\n* Pulmonary hypertension confirmed by mean pulmonary arterial pressure (mPAP) over 20 mmHg measured by right heart catheter\n* At least once per year of follow-up data collection record\n\nExclusion Criteria:\n\n* Patients with missing baseline or follow-up data\n* Complicated by other diseases with significant influence on survival, such as acute coronary syndrome, malignancy, etc.\n* Complicated by other diseases with significant influence on hemodynamics, such as sepsis, acute left heart failure, and acute pulmonary embolism, etc.\n* Receiving medications with significant influence on hemodynamics",{"count":154,"type":22},5000,"The goal of this observational study is to learn about pulmonary hypertension crisis (PHC) - a severe, and often fatal complication - in patients with pulmonary hypertension (PH). The main questions this study aims to answer are:\n\nWhat are the clinical and hemodynamic features of PHC, and what underlying pathophysiological mechanisms cause it to develop? Can these features be used to diagnostic PHC, predict who is at risk of developing it or dying from it, and develop targeted prevention and treatment of PHC?\n\nA multi-center registry platform and biobank will be established to enroll and follow up patients with PH. Clinical data, hemodynamic measurements, and biological specimen will be collected. Risk prediction and early warning tools of PHC will be developed.",[157,158],"Pulmonary Hypertension","Pulmonary Hypertension Crisis",[160,161,162,163],"Pulmonary hypertension","Pulmonary hypertension crisis","Diagnosis","Risk factor","2026-06-17",{"date":166,"type":39},"2026-06-22",{"date":164,"type":39},{"date":169,"type":22},"2029-12-31",{"name":45,"class":46},4,{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":23,"phases":181,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":186,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":47},"100641285","phase-1-analyse-of-diagnosis-value-of-keloid-on-68ga-rgd-pet-ct-100641285","NCT07660406","Analyse of Diagnosis Value of Keloid on 68Ga-RGD PET-CT","Inclusion Criteria:\n\n\\- Patients with a clinical diagnosis of keloids Able to obtain informed consent\n\nExclusion Criteria:\n\n\\- Pregnant women, children, patients with allergies to contrast media Patients with claustrophobia","80 Years",{"count":180,"type":22},30,[182,25],"PHASE1","Keloids are often described as benign dermal fibroproliferative lesions characterized by increased growth beyond the boundaries of the original wound margin.Fibroblasts are considered to be the key cellular mediators of fibrogenesis in keloid scars. Thus this prospective study is going to investigate whether 68Ga-RGD PET\u002FCT may provide evidence for diagnosis and evaluate the effectiveness of treatment.",[185],"Keloid",{"date":166,"type":39},{"date":188,"type":39},"2024-08-01",{"date":190,"type":22},"2027-10",{"name":45,"class":46},{"id":193,"slug":194,"hasResults":12,"nctId":195,"briefTitle":196,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":23,"phases":201,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":47},"100473796","lenalidomide-in-the-treatment-of-mucosal-behets-syndrome-100473796","NCT05449548","Lenalidomide in the Treatment of Mucosal Behçet's Syndrome","Inclusion Criteria:\n\n* Patients that can understand and voluntarily sign an informed consent document prior to the study;\n* Male and female subjects ≥ 18 years and ≤ 65 years of age at the time of signing the informed consent document.\n* Fulfilling the ICBD (International Conference on Behcet's Disease) criteria(2013);\n* Presented with active mucosal lesions: Subjects must have at least 1 oral ulcer within 4 weeks after the screening visit and at least 2 oral ulcers on the day of enrollment; subjects may be with or without genital ulcers and (or) skin lesions.\n* Refractory mucosal lesions: Subjects must experience at least 2 relapses of oral ulcers during 3 consecutive months of conventional treatment with corticosteroids and(or) immunosuppressants.\n* Without major organ involvement, including active gastrointestinal, ocular, nervous system, and major vessel involvement; previous major organ involvement is allowed if it occurred at least 1 year prior to the screening visit and is not active at the time of enrollment.; subjects with arthritis are permitted.\n\nExclusion Criteria: The presence of any of the following will exclude a subject from the study enrollment.\n\nExclusion Criteria:\n\n* Pregnant women or breastfeeding mothers, Male and female patients with recent fertility requirements.\n* Skin and mucosal lesions should exclude erythema multiforme, syphilis, Sweet disease, Stevens-Johnson syndrome, acne vulgaris, herpes simplex infection, periodic granulocytopenia, and acquired immunodeficiency.\n* Subjects with Behçet's syndrome-related active major organ involvement that requires aggressive immunosuppressive therapy, including active gastrointestinal, ocular, nervous system, and major vessel involvement.\n* Severe Concomitant disease: including heart failure(≥level Ⅲ, NYHA), respiratory failure, renal insufficiency (Serum creatinine ≥ 1.5 mg\u002FdL ), hepatic insufficiency(Aspartate transaminase (AST) and alanine transaminase (ALT) ≥ 2 X ULN.), myelosuppression(WBC\\\u003C3.0×109\u002FL or N\\\u003C1.5×109\u002FL, HGB≤85g\u002FL, PLT\\\u003C100×109\u002FL), peripheral neuropathy.\n* Acute severe infections such as sepsis and cellulitis, active hepatitis B or C virus infection, active tuberculosis, and history of a positive test for, or any clinical suspicion of, human immunodeficiency virus (HIV).\n* Patients with malignancy, or any history of malignancy within the 5 years prior to the screening phase, risk factors for myocardial infarction (including a history of thrombosis), or hypercoagulability.\n* History of use of lenalidomide or thalidomide within 1 month before enrollment.\n* Patients with allergies or contraindications to lenalidomide or thalidomide.\n* Having received concomitant immune-modulating therapy or small molecule drugs. At least 5 terminal half-lives for all biologics, including, but not limited to, those listed below; within:\n\nTen days prior to the day of enrollment for tofacitinib and baricitinib Four weeks prior to the day of enrollment for etanercept Eight weeks prior to the day of enrollment for infliximab Ten weeks prior to the day of enrollment for adalimumab, golimumab, certolizumab, abatacept, and tocilizumab Six months prior to the day of enrollment for secukinumab","65 Years",{"count":200,"type":22},42,[58],"The study is to evaluate the efficacy and safety of lenalidomide in the treatment of oral ulcers in adult patients with refractory mucosal Behcet's syndrome.",[204],"Oral Ulcer",{"date":166,"type":39},{"date":207,"type":39},"2023-04-01",{"date":209,"type":22},"2026-12-31",{"name":45,"class":46},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":223,"conditions":224,"keywords":227,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":47},"100641108","early-phase-1-safety-and-efficacy-study-of-pumch-e111-injection-in-subjects-with-rlbp1-related-inherited-retinal-dystrophy-100641108","NCT07656753","Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy","An Open-Label, Single-Center, Dose-Escalation Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Intravitreal Injection of PUMCH-E111 in Subjects With RLBP1 Related Inherited Retinal Dystrophy","Inclusion Criteria:\n\n1. Subjects voluntarily participate and sign the informed consent form;\n2. Age between 18-55 years old, gender is not limited;\n3. Clinical diagnosis of IRD caused by RLBP1 mutations;\n4. For the study eye, residual visual field within the 30° central field is tested using Program G or Program LVC on the Octopus perimeter;\n5. At screening, the blood pregnancy test result of females of childbearing potential (e.g., females who have not undergone surgical sterilization or less than 1 year after menopause) is negative. Male and female subjects of childbearing potential agree to use effective contraception throughout the study and for at least 12 months after dosing.\n\nExclusion Criteria:\n\n1. Opacity of refractive media or inability to dilate pupils in the study eye that significantly interferes with visual acuity detection, anterior segment or fundus assessment;\n2. Presence of diabetic retinopathy, retinal vein occlusion, pathological myopia, retinal detachment, or other conditions in the study eye that are assessed by the investigator as affecting the safety of the subject or the validity of the study;\n3. Active intraocular or periocular infection (such as blepharitis, conjunctivitis, keratitis, scleritis, etc.) in the study eye;\n4. History of vitreous hemorrhage in the study eye within 6 months prior to screening;\n5. Any intraocular surgery in the study eye within 3 months prior to screening;\n6. History of glaucoma in either eye；\n7. History of uveitis in either eye；\n8. Those with diffuse intravascular coagulation and obvious bleeding tendency (such as hemoptysis, hematemesis, severe purpura, etc.) within 3 months before screening;\n9. History of myocardial infarction, unstable angina, coronary revascularization, cerebrovascular accident (including TIA), history of other thromboembolic diseases (such as thromboembolic angiitis, pulmonary embolism, deep vein thrombosis, portal vein thrombosis, etc.), New York Heart Association (NYHA) grade ≥ II cardiac insufficiency, severe unstable ventricular arrhythmia, within 6 months prior to screening;\n10. Subjects with systemic immune diseases (including systemic lupus erythematosus, ankylosing spondylitis, rheumatoid arthritis, etc.);\n11. Diabetic patients with any of the following conditions: Known macrovascular complications or Glycosylated hemoglobin at screening（HbA1c）\\>7.5% or Those who have received more than two oral hypoglycemic drugs or received insulin or GLP-1 receptor agonists therapies;\n12. Hypertensive patients with poor blood pressure control (defined as: systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥100 mmHg when the subject is seated after receiving antihypertensive medication);\n13. Any uncontrollable clinical illness (such as severe psychiatric, respiratory and other systemic diseases and history of malignant tumors);\n14. Subjects with abnormal liver and kidney function: alanine aminotransferase (ALT)\u002Faspartate aminotransferase (AST) ≥ 2 times the upper limit of normal; Total bilirubin ≥ 1.5 times the upper limit of normal, creatinine and urea\u002Furea nitrogen ≥ 1.5 times the upper limit of normal;\n15. Subjects with abnormal coagulation function: prothrombin time (PT) \\> upper limit of normal value of 3 seconds or activated partial thromboplasting time (APTT) \\> upper limit of normal value of 10 seconds; Haemoglobin (HGb) \\\u003C 10 g\u002FdL;\n16. Those who are positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, treponema pallidum antibody and human immunodeficiency virus (HIV) antibody;\n17. Those who are known to be allergic to the therapeutic drugs or diagnostic drugs used in the study protocol, including the investigational products, etc.;\n18. Those who have used anticoagulant or antiplatelet drugs within 7 days before dosing;\n19. Currently using or may need to use drugs that can cause crystalline toxicity or retinal toxicity (such as deferoxamine, chloroquine\u002Fhydroxychloroquine, tamoxifen, ethambutol, etc.);\n20. Those who have a history of surgical operation within 1 month before screening, and\u002For currently have unhealed wounds (wound degree\\> stage III), moderate to severe ulcers, and fractures;\n21. Subjects with systemic infectious diseases requiring systemic treatment (oral, intramuscular or intravenous) at the time of screening;\n22. Those who have received any AAV gene therapy products in the past;\n23. Pregnant or lactating females;\n24. Those who have participated in any clinical trial of drugs (excluding vitamins and minerals) within 3 months before screening;\n25. Other individuals who need to be excluded, as determined by the investigator","55 Years",{"count":220,"type":22},6,[222],"EARLY_PHASE1","The goal of this clinical trial is to evaluate the safety and efficacy of PUMCH-E111 injection in subjects with RLBP1 related Inherited Retinal Dystrophy.",[225,226],"Inherited Retinal Dystrophy","Inherited Retinal Disease",[228,229],"inherited retinal dystrophy","RLBP1 mutation","2026-06-15",{"date":232,"type":39},"2026-06-18",{"date":234,"type":39},"2026-02-03",{"date":236,"type":22},"2031-05-31",{"name":45,"class":46},{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":245,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":47},"100627802","phase-2-orelabrutinib-in-the-treatment-of-relapsedrefractory-aiha-100627802","NCT07453368","Orelabrutinib in the Treatment of Relapsed\u002FRefractory AIHA","Orelabrutinib in the Treatment of Relapsed\u002FRefractory Autoimmune Hemolytic Anemia: A Prospective, Dose-Escalation Cohort Study","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Patients with a definitive diagnosis of AIHA. wAIHA or Evans syndrome, primary or secondary to connective tissue disease (CTD) or lymphoproliferative disorder (LPD). If secondary, CTD should have no indication for treatment for other system involvement, and LPD should be in an asymptomatic, observation phase without treatment indication.\n\ncAIHA, primary or secondary to LPD. If secondary, LPD should be in an asymptomatic, observation phase without treatment indication.\n\n* For wAIHA: No response (no partial response after 3 weeks) to full-dose glucocorticoid therapy (1-2 mg\u002Fkg\u002Fday), intolerance, or relapse (after initial response, hemoglobin drop ≥20 g\u002FL or requiring re-initiation of immunosuppressive therapy). And hemoglobin ≤ 100 g\u002FL.\n* For cAIHA: No response or relapse after anti-CD20 monoclonal antibody therapy (after initial response, hemoglobin drop ≥20 g\u002FL or recurrence of vascular symptoms, or requiring re-initiation of immunosuppressive therapy), or unsuitable for anti-CD20 therapy. And hemoglobin ≤ 100 g\u002FL or presence of vascular symptoms.\n* Baseline liver and kidney function (ALT, Cr) within 2 times the upper limit of normal (elevated AST, LDH, Bil due to hemolysis are not used as indicators for liver function assessment).\n* Agreement to sign the informed consent form.\n\nExclusion Criteria:\n\n* Active involvement of other major organs due to connective tissue disease.\n* Uncontrolled infection or bleeding per standard treatment.\n* Uncontrolled active HIV, HCV, or HBV infection per standard treatment.\n* Concurrent advanced uncontrolled malignancy, lymphoma.\n* Presence of other uncorrected types of anemia at screening, such as nutritional anemia, thalassemia, etc.\n* Currently receiving glucocorticoid therapy at screening and unable to discontinue or taper to ≤ 15 mg\u002Fday (prednisone equivalent) within 1 week before enrollment.\n* Currently receiving treatment with medications such as cyclosporine, tacrolimus, sirolimus, cyclophosphamide, azathioprine, stanozolol, testosterone undecanoate, danazol, etc., at screening, and the treatment duration at a stable dose is \\\u003C 12 weeks, or unable to discontinue directly.\n* Last dose of rituximab \\\u003C 3 months prior to enrollment.\n* Prior treatment with any BTK inhibitor.\n* Liver cirrhosis or portal hypertension.\n* Pregnant or breastfeeding women.\n* Participation in another clinical trial within the past 3 months.","85 Years",{"count":247,"type":22},50,[25],"1. wAIHA Treatment Regimen: Group A (50mg group): Orelabrutinib 50 mg, orally, once daily. After 4 weeks of treatment, if still transfusion-dependent or hemoglobin increase is \\\u003C 20 g\u002FL, the dose may be increased to 100 mg qd. Treatment can be discontinued if ineffective at 12 weeks.\n\n   Group B (100mg group): Orelabrutinib 100 mg, orally, once daily. The treatment course is at least 12 weeks. Treatment can be discontinued if ineffective at 12 weeks. Patients who respond and tolerate the drug well may continue treatment for up to 52 weeks or longer to observe long-term efficacy and safety.\n2. cAIHA Treatment Regimen: Group C (150mg group): Orelabrutinib 150 mg, orally, once daily. The treatment course is at least 12 weeks. Patients who respond and tolerate the drug well may continue treatment for up to 52 weeks or longer to observe long-term efficacy and safety.",[251],"Autoimmune Hemolytic Anemia (AIHA)",[253,254,255,256],"Autoimmune Hemolytic Anemia","Orelabrutinib","Treatment","Cohort Study",{"date":258,"type":39},"2026-06-16",{"date":260,"type":39},"2026-03-01",{"date":262,"type":22},"2028-03-01",{"name":45,"class":46},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":4,"eligibilityCriteria":270,"healthyVolunteers":12,"sex":17,"minAge":271,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":277,"conditions":278,"keywords":282,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":288,"startDateStruct":289,"completionDateStruct":290,"leadSponsor":292,"locationsCount":220},"100610585","phase-4-tegileridine-for-postoperative-pain-after-adolescent-scoliosis-surgery-100610585","NCT07229495","Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery","Efficacy and Safety of Tegileridine for Postoperative Analgesia Following Adolescent Scoliosis Correction Surgery: A Prospective, Multicentre, Double-Blind, Non-Inferiority, Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 10 years to less than 18 years.\n* Scheduled to undergo posterior spinal fusion (PSF) surgery for scoliosis under general anesthesia.\n* American Society of Anesthesiologists (ASA) physical status classification I to III.\n* The participant and their parent or legal guardian voluntarily provide written informed consent prior to any study-related procedures.\n\nExclusion Criteria:\n\n* History of difficult airway, severe respiratory depression (SpO₂ \\\u003C 90%), acute or severe bronchial asthma.\n* History of severe cardiovascular or cerebrovascular disease, such as myocardial infarction, unstable angina, second-degree or higher atrioventricular block, NYHA Class III or higher heart failure, or stroke.\n* Known or suspected gastrointestinal obstruction, including paralytic ileus.\n* Known hypersensitivity to opioids or any component of the study drug formulation.\n* History of psychiatric disorders (e.g., schizophrenia, depression) or cognitive impairment.\n* Diagnosis of neuromuscular scoliosis or presence of any other chronic pain condition that may interfere with postoperative pain assessment.\n* Chronic use of opioid analgesics or use of any analgesic medication within 48 hours prior to surgery.\n* Planned postoperative admission to the intensive care unit (ICU).\n* Any other condition deemed by the investigator to be inappropriate for participation in the study.","10 Years","17 Years",{"count":274,"type":22},171,[276],"PHASE4","The goal of this clinical trial is to see if a new pain medicine called Tegileridine is at least as effective as morphine (the standard treatment) for pain relief after spinal surgery in teenagers with scoliosis. This type of study is called a \"non-inferiority\" trial. The study will also carefully compare the safety of both medicines.\n\nThe main questions it aims to answer are:\n\nIs Tegileridine no worse than morphine at controlling pain in the first 24 hours after surgery? How do the side effects (like sleepiness or nausea) of Tegileridine compare to those of morphine? Researchers will compare two different doses of Tegileridine against morphine. Neither the participants nor the doctors assessing them will know which medicine is being given.\n\nParticipants in this study will:\n\nReceive one of the three pain medicine options through a pump (called a PCA pump) that they can control themselves after surgery.\n\nUse the pump for up to 48 hours. Regularly rate their pain levels using a simple number scale. Have their health closely monitored by the study team during this time.",[279,280,281],"Scoliosis; Adolescence","Pain After Surgery","Analgesia, Patient-controlled",[283,284,285,286,287],"Tegileridine","Postoperative Pain","Adolescent","Patient-Controlled Analgesia","Scoliosis",{"date":164,"type":39},{"date":38,"type":22},{"date":291,"type":22},"2027-09-30",{"name":45,"class":46},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":17,"minAge":300,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":308,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":321},"100641815","ai-for-rare-disease-diagnosis-in-real-world-100641815","NCT07650799","AI for Rare Disease Diagnosis in Real World","A Multicentre, Prospective, Cluster-Randomised, Parallel-Controlled Trial of a Rare-Disease Large Language Model in Real-World Clinical Settings","Patient Inclusion Criteria:\n\n* Any age. Legal guardian co-signs consent for minors or individuals lacking legal capacity.\n* Diagnostically unresolved or suspected rare disease, with at least one prior complete clinical evaluation at a secondary-level or higher institution yielding no confirmed explanatory diagnosis.\n* First presentation to the enrolling institution for the current condition, with no prior records in the institutional HIS or outpatient system.\n* No prior genetic testing related to the current condition; no results or reports available.\n* Written informed consent provided voluntarily by patient or legal guardian, with commitment and ability to complete structured follow-up.\n\nPatient Exclusion Criteria:\n\n* Confirmed diagnosis (clinical, pathological, or molecular) explaining the primary symptoms.\n* Emergency presentation, critical illness, or any condition incompatible with trial participation.\n* Neither patient nor legally authorised proxy able to complete follow-up.\n* Concurrent enrollment in another interventional study with diagnostic accuracy or genetic testing yield as a primary endpoint.\n* Prior use of another AI system has already yielded a confirmed diagnosis for the current condition.\n\nPhysician Inclusion Criteria\n\n* Licensed physician in internal medicine, neurology, pediatrics, general medicine, rare disease, or a related specialty.\n* ≥2 years of clinical practice; competent to manage rare disease patients; stratified into junior or senior tier.\n* Voluntary participation with written informed consent.\n\nPhysician Exclusion Criteria\n\n* No longer in clinical practice, or unable to fulfill required outpatient duties during the study period.\n* Unwilling to provide informed consent or to permit protocol-required collection of consultation and questionnaire data.\n* Currently enrolled in another AI-assisted clinical workflow, or expected to be unable to comply with the procedures.","0 Years",{"count":302,"type":22},1055,[58],"A multicentre, prospective, cluster-randomised, parallel-controlled real-world effectiveness study evaluating whether a rare-disease diagnostic large language model can improve diagnostic quality, efficiency, and health-economic outcomes for physicians managing patients with suspected rare or diagnostically unresolved disease.",[306,307],"Rare Disorders","Rare Diseases",[309,310,311,312,313],"rare diseases","AI","LLM","diagnosis","cost-effectiveness","2026-06-14",{"date":258,"type":39},{"date":317,"type":22},"2026-06-20",{"date":319,"type":22},"2027-12-01",{"name":45,"class":46},13,{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":329,"minAge":18,"maxAge":330,"enrollmentInfo":331,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":342,"startDateStruct":343,"completionDateStruct":344,"leadSponsor":346,"locationsCount":4},"100642503","hal-pdt-for-cervical-intraepithelial-neoplasia-grade-2-100642503","NCT07634497","HAL-PDT for Cervical Intraepithelial Neoplasia Grade 2","A Prospective, Multicenter Real-world Study of HAL-PDT for Cervical Intraepithelial Neoplasia Grade 2","Inclusion Criteria:\n\n1. Voluntarily participate in this clinical study, fully understand the study content, procedures, and potential adverse reactions, and be able to sign the written informed consent form.\n2. Able to complete the study in accordance with the study protocol.\n3. Female aged ≥18 years and ≤50 years.\n4. Newly diagnosed High-Grade Squamous Intraepithelial Lesion (HSIL), cervical intraepithelial neoplasia grade 2 (CIN2) within 3 months, specifically: CIN2 confirmed by tissue biopsy within 3 months prior to the first treatment.\n\n   Note: Histopathological diagnosis will be assessed by the pathology department of the participating hospital for enrollment.\n5. Adequate colposcopy, including:\n\n   * Complete visibility of the cervical transformation zone, including the squamocolumnar junction;\n   * Complete visibility of lesion margins;\n   * No lesion extension into the cervical canal.\n6. Cervical size deemed suitable for placement of the HAL-PDT device as assessed by the investigator according to the HAL-PDT package insert.\n7. Meets the following conditions: negative pregnancy test; no plan for pregnancy during the study period; no sexual activity or use of effective and reliable contraception from the end of the last menstrual period to the start of the study, and agreement to use condoms for barrier contraception during the study period.\n\nExclusion Criteria:\n\nSubjects who meet any of the following criteria will be excluded from this study:\n\n1. Cervical adenocarcinoma in situ or other glandular lesions, invasive cervical cancer, or suspected malignant lesions.\n2. Lesions extending to the vaginal wall, cervical canal, or vaginal fornix, or lesions located on the vulva.\n3. Prior treatment (surgical or physical therapy) for the condition, or receipt of physical or surgical therapy within 3 months after the current histopathological diagnosis of CIN2.\n4. The date of the first HAL-PDT treatment falls within 7 half-lives of the last antiviral medication.\n5. History of toxic shock syndrome.\n6. Severe pelvic inflammatory disease, severe cervicitis, or other severe gynecological infectious diseases found on colposcopic or clinical examination.\n7. Investigator judges that vaginal bleeding during treatment may affect treatment outcomes.\n8. Receipt of any inactivated vaccine within 2 weeks prior to the first treatment, or any live vaccine within 4 weeks prior to the first treatment.\n9. Previous severe cardiovascular, cerebrovascular, neurological, psychiatric, endocrine, or hematopoietic disease that has not been cured; known severely compromised immune function, or need for long-term use of corticosteroids or immunosuppressants; history of malignancy within 5 years.\n10. History of clinically significant immunosuppression or confirmed autoimmune disease; or primary immunodeficiency.\n11. Known or newly identified active sexually transmitted diseases (STDs), including but not limited to HIV, syphilis, genital herpes, unless adequately treated and tested negative before study treatment.\n12. Presence of a cardiac pacemaker.\n13. Suspected or known porphyria, or known allergy to hexaminolevulinate, its chemically similar compounds, or photosensitizers.\n14. Allergy to silicone.\n15. Pregnant or breastfeeding women.\n16. Delivery or miscarriage within 6 weeks prior to enrollment.\n17. Participation in any other clinical trial within 30 days prior to HAL-PDT treatment.\n18. Poor compliance or judged by the investigator to be unsuitable for participation in this clinical study.","FEMALE","50 Years",{"count":106,"type":22},"This is a prospective, multicenter real-world study evaluating the effectiveness and safety of hexaminolevulinate photodynamic therapy (HAL-PDT) in patients with cervical intraepithelial neoplasia grade 2 (CIN2). Treatment is guided by colposcopic response: patients receive 2, 3, or 4 sessions of HAL-PDT based on lesion persistence at Day 60 and Day 90 assessments. The primary endpoint is histopathological regression rate at 6 months after first treatment. Secondary endpoints include histopathological regression at 12 months, HPV clearance at 6 and 12 months, and safety. A total of 500 patients will be enrolled.",[334],"Cervical Intraepithelial Neoplasia Grade 2 (CIN2)",[336,337,338,339,340],"Hexaminolevulinate Photodynamic Therapy","HAL-PDT","CIN2","HPV","Real-World Study","2026-06-12",{"date":258,"type":39},{"date":230,"type":22},{"date":345,"type":22},"2029-12-15",{"name":45,"class":46},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":355,"conditions":356,"keywords":359,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":47},"100641384","hemodynamic-effects-of-norepinephrine-reduction-on-critical-closing-pressure-in-distributive-shock-100641384","NCT07653659","Hemodynamic Effects of Norepinephrine Reduction on Critical Closing Pressure in Distributive Shock","Changes in Critical Closing Pressure and Derived Hemodynamic Parameters Following Norepinephrine Dose Reduction in Distributive Shock Patients: a Prospective Observational Study","Inclusion Criteria:\n\n1. Adult distributive shock patients aged ≥18 years;\n2. Receiving norepinephrine infusion with MAP in the 75-85 mmHg range;\n3. PiCCO catheter in situ;\n4. Under mechanical ventilation;\n5. Clinically indicated norepinephrine dose reduction per attending physician judgment.\n\nExclusion Criteria:\n\n1. Significant cardiac arrhythmia affecting CO measurement reliability;\n2. Contraindication to airway plateau pressure maneuver;\n3. Active titration of other vasoactive agents within 30 minutes prior to measurement;\n4. Hemodynamic instability making it impossible to reduce norepinephrine dose.",{"count":180,"type":22},"This study prospectively observes changes in critical closing pressure (Pcc) and derived hemodynamic parameters in mechanically ventilated distributive shock patients when clinically indicated norepinephrine dose reduction is performed by the attending physician. Pcc is measured before and 30 minutes after dose reduction using a stepwise inspiratory hold maneuver via PiCCO monitoring.",[357,358,64],"Distributive Shock","Hemodynamic Assessment",[360,361,362,363,364],"Critical closing pressure","Tissue perfusion pressure","Vascular waterfall","Norepinephrine dose","Distributive shock",{"date":164,"type":39},{"date":367,"type":39},"2025-09-01",{"date":369,"type":22},"2027-09-01",{"name":45,"class":46},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":4},"100641405","phase-3-rhtpo--csa-vs-csa-in-the-treatment-of-lr-mds-with-thrombocytopenia-100641405","NCT07653581","rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia","rhTPO + CsA Versus CsA Alone in the Treatment of Lower-risk MDS With Thrombocytopenia: a Single-center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Confirmed diagnosis of lower-risk MDS;\n3. Platelet ≤ 30×109\u002FL, or \\\u003C 50×109\u002FL and accompanied by bleeding events;\n4. Baseline liver and kidney functions \\\u003C2 ULN;\n5. Signed the informed consent form;\n6. ECOG 0-2;\n\nExclusion Criteria:\n\n1. History of leukemia or stem cell transplantation, treatment-related MDS or malignant tumors;\n2. With splenomegaly or myelofibrosis;\n3. Infections or bleeding that cannot be controlled by standard treatment;\n4. Any concurrent malignant tumors within the past 5 years, or basal cell carcinoma of the skin at the local site;\n5. History of thromboembolic events, heart attack or stroke and current use of anticoagulants;\n6. Previously received cyclosporine (CsA) or ATG within 6 months;\n7. Previously used IL-11, rhTPO or TPO-RA;\n8. Pregnant or lactating women;\n9. Participated in other clinical trials within 3 months.",{"count":379,"type":22},78,[134],"This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.",[383],"Lower-risk Myelodysplastic Syndromes","2026-06-11",{"date":164,"type":39},{"date":387,"type":22},"2026-06",{"date":389,"type":22},"2029-12",{"name":45,"class":46},{"id":392,"slug":393,"hasResults":12,"nctId":394,"briefTitle":395,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":178,"enrollmentInfo":399,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":407,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":421},"100585467","phase-4-pcsk9-inhibitor-with-statin-therapy-for-asymptomatic-intracranial-atherosclerosis-100585467","NCT06902740","PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis","PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis (PISTIAS-2): A Multicenter, Open-label, Blinded-endpoint, Randomized Controlled Trial","PISTIAS-2","Inclusion Criteria:\n\n1. Age ≥18 and ≤80, male or female;\n2. Asymptomatic intracranial artery stenosis (50%-99%) in the internal carotid artery (C6-7 segments), middle cerebral artery (M1 segment), vertebral artery (V4 segment), or basilar artery, confirmed by angiography (MRA, CTA, or DSA);\n3. Atherosclerosis identified as the cause of intracranial artery stenosis by high-resolution magnetic resonance imaging;\n4. No previous ischemic cerebrovascular events (including ischemic stroke or transient ischemic attack).\n5. Baseline low-density lipoprotein cholesterol ≥ 1.8 mmol\u002FL;\n6. Informed consent signed.\n\nExclusion Criteria:\n\n1. Non-atherosclerotic intracranial artery stenosis, including arterial dissection; moya moya disease; systemic vasculitis and primary central nervous system vasculitis; varicella-zoster vasculopathy or other viral vasculopathy; neurosyphilis and other intracranial infections, radiation vasculopathy; fibromuscular dysplasia, sickle cell disease, neurofibromatosis; reversible cerebral vasoconstriction syndrome; postpartum vasculopathy; suspected vasospasm, suspected reperfusion after vessel occlusion.\n2. Upstream tandem extracranial vessel stenosis (≥50%) adjacent to the target intracranial stenotic vessel.\n3. Previous treatment of target intracranial lesion with endovascular intervention or plan to perform endovascular intervention within 6 months, including intracranial stenting, endovascular angioplasty, and thrombectomy.\n4. Any intracranial hemorrhage (parenchymal, subarachnoid, subdural, extradural, intraventricular) within 90 days prior to enrollment.\n5. Presence of intracranial tumors.\n6. Presence of cerebral aneurysms or arteriovenous malformations with indications for interventional therapy.\n7. Major surgery (including open femoral, aortic, or carotid surgery) within previous 30 days or planned in the next 6 months after enrollment.\n8. Presence of any of the following unequivocal cardiac sources of embolism: mitral stenosis, mechanical valve, endocarditis, intracardiac clot or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, chronic or paroxysmal atrial fibrillation.\n9. New York Heart Association (NYHA) class III or IV, or known left ventricular ejection fraction \\\u003C 30%.\n10. Severe liver dysfunction or severe kidney dysfunction: AST and\u002For ALT \\> 3 times the ULN; creatinine clearance \\\u003C 0.6 mL\u002Fs and\u002For serum creatinine \\> 265 μmol\u002FL (\\>3.0 mg\u002FdL); CK \\>5 times the ULN at screening.\n11. Active bleeding diathesis or coagulopathy (e.g., active peptic ulcer disease, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets count \\\u003C 125,000 \u002F uL, hematocrit \\\u003C 30%, Hgb \\\u003C 10 g\u002Fdl, international normalized ratio \\>1.5, bleeding time \\> 1 minute beyond normal value upper limit).\n12. Presence of systemic autoimmune diseases: systemic sclerosis, systemic lupus erythematosus, Sjögren's syndrome, Behçet's disease, mixed connective tissue disease, IgG4-related disease.\n13. Dementia or psychiatric problem that hinder their ability to consistently adhere to an outpatient program. Co-morbid conditions that may limit the life expectancy to less than 3 years.\n14. Relative\u002Fabsolute contraindications to magnetic resonance imaging (MRI) (such as presence of internal metallic objects, claustrophobia, contrast agent allergy, severe renal impairment, epilepsy, hypotension, asthma, and other hypersensitivity respiratory diseases).\n15. Uncontrolled hypertension during the screening period, defined as seated systolic blood pressure (SBP) \\> 180 mmHg or diastolic blood pressure (DBP) \\> 110 mmHg.\n16. Prior use of PCSK9 inhibitor before this recruitment.\n17. Known intolerance or allergy to statin.\n18. Pregnancy, lactation, or planning pregnancy.\n19. Currently participating in another study.",{"count":400,"type":22},300,[276],"This is a prospective, multicenter, open-label, blinded-endpoint, randomized controlled trial designed to evaluate the efficacy and safety of PCSK9 inhibitor combined with statin therapy compared to statin monotherapy in reversing asymptomatic intracranial atherosclerosis, assessed using high-resolution magnetic resonance imaging of the intracranial vessel walls.",[404,405,406],"Intracranial Atherosclerosis","Intracranial Artery Stenosis","Atherosclerotic Plaque",[404,408,409,410,411,412,413],"intracranial artery stenosis","atherosclerotic plaque","high-resolution magnetic resonance imaging","PCSK9 inhibitor","statin","Recaticimab","2026-06-10",{"date":341,"type":39},{"date":417,"type":39},"2025-11-07",{"date":419,"type":22},"2028-12-31",{"name":45,"class":46},19,{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":439,"locationsCount":47},"100643566","adjuvant-therapy-for-high-risk-intrahepatic-cholangiocarcinoma-a-real-world-study-100643566","NCT07640048","Adjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study","A Real-World Study on Postoperative Adjuvant Therapy for Intrahepatic Cholangiocarcinoma Patients With High-Risk Recurrence Factors","Inclusion Criteria:\n\n* Histologically confirmed ICC within 12 weeks after curative resection\n* Any T stage; N0\u002FN+; M0.\n* At least one high-risk factor:\n\nPreoperative tumor penetration of the liver capsule or extrahepatic direct invasion; Preoperative imaging showing multifocal lesions or a single lesion \\>5 cm; Vascular invasion (preoperative or postoperative pathology); Regional lymph node metastasis.\n\n* No prior systemic therapy for ICC.\n* ECOG performance status 0-2.\n* Expected survival ≥3 months.\n* Adequate organ function.\n* Agreement to use effective contraception (or surgical sterilization) during the study and for 120 days after the last dose.\n* Signed informed consent and anticipated good compliance with the study protocol.\n\nExclusion Criteria:\n\n* Immunosuppressive therapy within 28 days prior to enrollment (excluding topical\u002Finhaled corticosteroids or physiologic steroid doses ≤10 mg\u002Fday prednisone equivalent).\n* Systemic anticancer herbs\u002Fimmunomodulators (e.g., thymosin, interferons) within 4 weeks, except for pleural effusion control.\n* Uncontrolled cardiovascular disease:\n\nUnstable angina\u002Fmyocardial infarction Arrhythmias with QTc ≥450 ms (men) or ≥470 ms (women) NYHA Class III-IV heart failure or LVEF \\\u003C50%\n\n* Active infections (IV antibiotics\u002Fantivirals required) or fever \\>38.5°C within 4 weeks; or major surgery within 3 weeks.\n* Active autoimmune\u002Fimmunodeficiency diseases (e.g., hepatitis, pneumonitis, rheumatoid arthritis), except:\n\nHypothyroidism on stable hormone replacement Type 1 diabetes with controlled glucose Uncontrolled asthma requiring systemic bronchodilators (resolved childhood asthma allowed).\n\n\\- Active infections: HIV\u002FAIDS\n\nHBV (DNA ≥500 IU\u002FmL) or HCV (RNA-positive) unless:\n\nHBV DNA \\\u003C500 IU\u002FmL + antiviral therapy ≥14 days\n\n* Prior\u002Fproposed organ transplantation (excluding corneal grafts).\n* Concurrent interventional trials or investigational drugs within 4 weeks without recovery to Grade ≤1 toxicity.\n* Hypersensitivity to study drug components.\n* Allogeneic transplant history\u002Fplans.\n* Uncontrolled psychiatric\u002Fsubstance abuse disorders.\n* Refractory hypertension (≥140\u002F90 mmHg despite treatment).\n* Clinically significant bleeding\u002Fthromboembolism:\n\nGI bleeding within 3 months Thrombotic events within 6 months (stroke, DVT\u002FPE)\n\n* Coagulopathy (INR \\>1.5, PT \\>ULN+4s, aPTT \\>1.5×ULN) or anticoagulant use.\n* Proteinuria ≥++ on dipstick or 24-h urine protein ≥1 g.\n* Other high-risk conditions per investigator judgment.",{"count":430,"type":22},90,"This multicenter real-world study assesses the efficacy and safety of adjuvant therapies in postoperative intrahepatic cholangiocarcinoma (ICC) patients with high-risk recurrence factors.\n\n90 eligible patients will be assigned to: Cohort 1: GP (gemcitabine\u002Fcisplatin) + adebrelimab Cohort 2: Apatinib + adebrelimab Cohort 3: S-1 (tegafur\u002Fgimeracil\u002Foteracil) + adebrelimab Outcomes will be compared against historical real-world controls receiving standard chemotherapy.",[433],"Intrahepatic Cholangiocarcinoma (Icc)","2026-06-05",{"date":414,"type":39},{"date":437,"type":39},"2025-05-04",{"date":169,"type":22},{"name":45,"class":46},{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":447,"targetDuration":4,"studyType":23,"phases":449,"briefSummary":450,"conditions":451,"keywords":453,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":456,"startDateStruct":457,"completionDateStruct":458,"leadSponsor":459,"locationsCount":47},"100643440","phase-2-faecal-microbiota-transplantation-in-patients-with-refractory-rheumatoid-arthritis-100643440","NCT07639177","Faecal Microbiota Transplantation in Patients With Refractory Rheumatoid Arthritis","Efficacy and Safety of Lyophilised Oral Faecal Microbiota Transplantation in Patients With Active Refractory Rheumatoid Arthritis- A Randomized Controlled Study","Inclusion Criteria:\n\n1. Age 18-65 years with informed consent;\n2. Fulfill the 2010 ACR\u002FEULAR classification criteria for rheumatoid arthritis;\n3. Positive RF or anti-CCP antibody on screening;\n4. Active disease status with swollen joint count(SJC)≥3 and tender joint count(TJC)≥3 and ESR \\>25 mm\u002Fhr or hypersensitive C-reactive protein \\> 10 mg\u002FL;\n5. Having received csDMARDs including but not limited to methotrexate (at a stable dose of 7.5 - 20 mg\u002Fweek) for 3 months or longer prior to screening and willing to continue current regimen for the duration of the study;\n6. Other csDMARDs (e.g. Leflunomide, Iguratimod, Sulfasalazine, Hydroxychloroquine, Tripterygium Wilfordii, etc.) taking before screening with dosage stablized for 3 months or longer are permitted and should continue during the duration of the study;\n7. Class I, II or III of the ACR 1991 Revised Criteria for Global Functional Status in RA;\n8. If taking non-steroidal anti-inflammatory drugs (NSAIDs), must be at a stable dose for at least two weeks prior to screening;\n9. Female subjects must have a negative pregnancy test unless they are surgically sterile or have been post-menopausal for at least one year (12 consecutive months without menses) ;\n10. Participants with fertility must use a medically effective form of contraception and agree to continue its use during the study or at least 3 monts after the last dose of study intervention.\n11. Willing to suspend the use of other adjuvant treatment for the duration of the study including acupuncture, massage, etc.\n\nExclusion Criteria:\n\n1. Pregnant, lactating or further fertility requirements\n2. History of any inflammatory rheumatological disorders other than RA;\n3. Having used biologics or small-molecular targeting agents in 6 months prior to screening;\n4. Taking oral glucocorticoid (GC) or get GC injection (intra-articular or parenteral) in one month prior to screening;\n5. Severe, progressive, or uncontrolled visceral disease including cardiac, pulmonary, renal, hepatic, gastrointestinal, hematologic, metabolic, endocrine or neurologic disease;\n6. Severe enteritis, intestinal obstruction or bleeding, or history of gastrointestinal surgery.\n7. Active infection in recent 3 months or persistent chronic infection, including HIV, HCV, HBV, tuberculosis;\n8. Malignancy or history of malignancy;\n\n8\\. Other conditions that investigators consider inappropriate for this study.",{"count":448,"type":22},40,[25],"In this 24-week, single center, randomized, double-blind, placebo-controlled study, the efficacy and safety of lyophilised oral fecal microbiota transplantation in patients with active refractory rheumatoid arthritis will be evaluated.",[452],"Rheumatoid Arthritis",[454,455],"Faecal Microbiota Transplantation","Refractory Rheumatoid Arthritis",{"date":414,"type":39},{"date":230,"type":22},{"date":419,"type":22},{"name":45,"class":46},{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":466,"sex":17,"minAge":18,"maxAge":467,"enrollmentInfo":468,"targetDuration":470,"studyType":108,"phases":4,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":47},"100643441","study-on-the-diagnostic-cut-off-point-of-24-hour-urinary-aldosterone-measured-by-liquid-chromatography-tandem-mass-spectrometry-in-the-diagnosis-of-primary-aldosteronism-in-the-oral-sodium-loading-test-100643441","NCT07635134","Study on the Diagnostic Cut-off Point of 24-hour Urinary Aldosterone Measured by Liquid Chromatography-Tandem Mass Spectrometry in the Diagnosis of Primary Aldosteronism in the Oral Sodium Loading Test","Inclusion criteria for the normal control group: Age 18-70 years old, BMI: 18.5-23.9kg\u002Fm ²，gender not restricted. blood pressure: 100-120\u002F60-80mmHg. no history of hypertension. No abnormal nodules found in adrenal CT. Previous blood potassium and electrocardiogram were all within normal ranges., No history of liver or kidney dysfunction, malignant tumors, metabolic diseases or cardiovascular diseases, and no medication used.\n\nExclusion criteria: Those with a family history of hypertension or with clinical manifestations of secondary hypertension. Those who have been taking drugs that may affect the RAAS system for a long time (such as contraceptives, steroids, etc.). Those with cardiac dysfunction or severe arrhythmia and unable to tolerate the test.\n\nPatients with suspected primary aldosteronism in the outpatient setting. Inclusion criteria: Patients with suspected primary aldosteronism in the outpatient setting. Willing to undergo 4-week spironolactone treatment and cooperate with follow-up.\n\nExclusion criteria: Patients who did not complete the oral sodium loading test. Patients with Cushing's syndrome or other endocrine tumors. Patients allergic to spironolactone or with contraindications for its use (such as severe hyperkalemia, eGFR \\\u003C 30).History of liver or kidney dysfunction, coexisting severe cardiovascular or cerebrovascular diseases, history of malignant tumors, other types of endocrine hypertension (hyperthyroidism, pheochromocytoma, Cushing's syndrome, etc.), renal artery stenosis, hypokalemia caused by other factors (renal tubular acidosis, Bartter syndrome, Gitelman syndrome, etc.), diabetes with HbA1c \\> 7.0% or currently using or having used insulin or SGLT2 inhibitor drugs, taking special medications such as glucocorticoids, immunosuppressants, oral contraceptives, etc.",true,"70 Years",{"count":469,"type":22},800,"6 Months","Primary aldosteronism (PA) is the most common cause of secondary hypertension. Liquid chromatography - tandem mass spectrometry (LC-MS\u002FMS) is more accurate than the traditional radioimmunoassay in measuring aldosterone. This study aims to establish a more precise diagnostic threshold for the oral sodium loading test (OSLT) by using LC-MS\u002FMS to measure urinary aldosterone levels. We will combine the biochemical results of OSLT and other data from healthy volunteers and suspected PA patients to determine a new 24-hour urinary aldosterone threshold. We expect to improve the diagnostic accuracy of PA, helping clinicians identify this curable cause of hypertension earlier and more accurately, and achieving precise treatment.",[473],"Primary Aldosteronism",[475,476],"the oral sodium loading test","diagnose","2026-06-03",{"date":479,"type":39},"2026-06-09",{"date":481,"type":39},"2025-04-01",{"date":483,"type":22},"2026-08-01",{"name":45,"class":46},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":466,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":23,"phases":494,"briefSummary":495,"conditions":496,"keywords":497,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":504,"locationsCount":321},"100638449","artificial-intelligence-for-rare-disease-diagnosis-100638449","NCT07625436","Artificial Intelligence for Rare Disease Diagnosis","A Multicentre, Randomised Diagnostic Accuracy Study Evaluating AI Assisted Diagnosis of Rare Diseases","Inclusion Criteria:\n\n* 1\\. Licensed physicians at the junior or senior level affiliated with internal medicine, neurology, pediatrics, and rare disease-related departments.\n* 2\\. Willingness to provide written informed consent, adhere to trial protocols, and complete all required pre-study training prior to enrollment.\n\nExclusion Criteria:\n\n* 1\\. Prior exposure to any of the clinical cases included in the study case library.\n* 2\\. Direct participation in the design or development of the AI model.",{"count":493,"type":22},150,[58],"A multicentre, randomised diagnostic accuracy study to evaluate whether the rare disease-specific AI can improve diagnostic accuracy and efficiency for physicians managing real-world clinical cases.",[306,307],[307,498,499,162],"Artificial Intelligence","Clinical Decision Support System (CDSS)",{"date":501,"type":39},"2026-06-04",{"date":317,"type":22},{"date":43,"type":22},{"name":45,"class":46},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":513,"conditions":514,"keywords":519,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":47},"100464686","screening-and-follow-up-in-patients-with-hiv-infection-combined-with-metabolic-associated-fatty-liver-disease-100464686","NCT05330923","Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver Disease","Inclusion Criteria:\n\n* Newly treated or treated AIDS patients;\n* Regular follow-up visits to the hospital, medication compliance is good;\n* Patients or their family members were willing to participate in the study by understanding the study plan and providing written informed consent.\n\nExclusion Criteria:\n\n* Unable to complete the position requirements of ultrasonic examination (lying flat) due to mobility difficulties;\n* Patients have poor compliance and cannot follow up regularly or take medicine on time;\n* Patients or family members cannot understand the conditions and objectives of the study;\n* Other conditions considered unsuitable for inclusion by the investigator.",{"count":512,"type":22},2000,"Acquired immunodeficiency syndrome (AIDS) remains a severe global infectious disease, with over 38 million people living with HIV and around 35 million cumulative deaths worldwide by 2023; approximately 1.24 million HIV-positive individuals and 100,000 new infections are reported annually in China. Widespread use of HAART has prolonged HIV patients' survival and reduced AIDS-related mortality, yet non-AIDS comorbidities dominated by chronic liver disorders, particularly metabolic dysfunction-associated fatty liver disease (MAFLD), have become a major challenge in long-term HIV management. Triggered by elevated blood lipids from lifestyle, antiretroviral agents and inherited metabolic factors, MAFLD initiates with hepatic steatosis and may progress to NASH, liver fibrosis, cirrhosis and even hepatocellular carcinoma (HCC) without timely intervention. HIV-positive patients develop more severe MAFLD progression than HIV-negative counterparts; existing biopsy data shows 91% of ART-treated HIV patients have NAFLD, among whom 65% suffer from NASH complicated with liver fibrosis.\n\nFatty liver prevalence keeps rising with younger onset age in China, which highlights the necessity of early screening. Liver biopsy, the historical diagnostic gold standard for liver injury grading, is restricted by invasiveness, bleeding risks and poor reproducibility. Transient elastography (TE), a novel non-invasive ultrasonic technique, quantifies hepatic steatosis via the ultrasound attenuation parameter (UAP) and liver fibrosis via liver stiffness measurement (LSM), and has been validated and guideline-endorsed for multiple chronic liver diseases globally. Published foreign data report 35%, 42% and 22% prevalence of NAFLD, NASH and fibrosis in PLWH, while domestic evidence on HIV-associated MAFLD is limited, especially liver-related discrepancies among varied ART regimens. With the implementation of China's new medical insurance policy, numerous patients are shifting from non-INI regimens to once-daily single-tablet INSTI STR regimens, whose hepatic and lipid impacts remain unclear. This study targets early detection of HIV patients with concomitant fatty liver to optimize management strategies and improve clinical outcomes.\n\nOur preliminary cohort at Peking Union Medical College Hospital included 188 virologically suppressed HIV patients on ART, 56.9% (107\u002F188) of whom developed fatty liver (mild:27.1%, moderate:19.7%, severe:10.1%). Liver fibrosis (LSM≥7.3 kPa) was found in 12.8% (24\u002F188) subjects, with 1.1% having advanced cirrhosis, and no significant inter-group difference in fatty liver incidence was noted between INSTI and NNRTI recipients. These findings lay a foundation for early diagnosis and follow-up intervention of metabolic liver disease among HIV-infected populations.",[515,516,517,518],"Nonalcoholic Fatty Liver Disease","Nonalcoholic Steatohepatitis","Fibrosis","HIV\u002FAIDS",[520,521,522,523],"integrase inhibitors","non-nucleoside reverse transcriptase inhibitors","transient elastography","iLivTouch","2026-06-02",{"date":501,"type":39},{"date":527,"type":39},"2022-01-01",{"date":529,"type":22},"2029-06-01",{"name":45,"class":46},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":4,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":198,"maxAge":4,"enrollmentInfo":538,"targetDuration":540,"studyType":108,"phases":4,"briefSummary":541,"conditions":542,"keywords":544,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":548,"lastUpdatePostDateStruct":549,"startDateStruct":550,"completionDateStruct":551,"leadSponsor":553,"locationsCount":47},"100637802","wearable-accelerometers-for-predicting-perioperative-risk-in-elderly-patients-100637802","NCT07621120","Wearable Accelerometers for Predicting Perioperative Risk in Elderly Patients","Utilization of Wearable Accelerometer in Predicting of Perioperative Autonomic Function and Postoperative Complications in Elderly Patients","Inclusion Criteria:\n\n* Age ≥65 years\n* Scheduled for elective non-cardiac surgery\n* American Society of Anesthesiologists (ASA) physical status I-III\n* Planned to undergo general anesthesia\n* Planned tracheal intubation\n* The patient and family members are able to understand the study protocol, are willing to participate, and provide written informed consent\n\nExclusion Criteria:\n\n* Severe vascular disease\n* Secondary hypertension\n* Limb tremor disorders, such as Parkinson disease\n* Inability to wear a wrist-based wearable accelerometer for any reason\n* Inability to measure upper-extremity blood pressure\n* Atrial fibrillation or other arrhythmias unsuitable for baroreflex sensitivity measurement\n* Mental or psychiatric conditions resulting in inability to cooperate with study procedures",{"count":539,"type":22},100,"3 Months","This single-center prospective cohort study is designed to evaluate whether preoperative physical activity measured by a wearable accelerometer is associated with cardiovascular autonomic function and whether it can help predict post-induction hypotension in elderly patients undergoing elective non-cardiac surgery. Patients aged 65 years or older scheduled for general anesthesia with tracheal intubation will undergo preoperative physical activity monitoring using an ActiGraph wearable accelerometer. Activity-related parameters, including sedentary time, light-, moderate-, and vigorous-intensity activity, daily step count, and sleep duration, will be recorded. Cardiovascular autonomic function will be assessed perioperatively using noninvasive continuous hemodynamic monitoring, with baroreflex sensitivity-related indices derived from continuous blood pressure and beat-to-beat timing data. The primary outcome is post-induction hypotension. Secondary outcomes include early intraoperative hypotension, postoperative complications, and 30-day mortality. This study aims to clarify the relationship between habitual physical activity and autonomic regulation in older surgical patients and to provide evidence supporting future prehabilitation strategies.",[543],"Post Induction Hypotension",[545,546,547],"post induction hypotension","elderly patient","wearable accelerometer","2026-06-01",{"date":524,"type":39},{"date":230,"type":22},{"date":552,"type":22},"2027-12-31",{"name":45,"class":46},{"id":555,"slug":556,"hasResults":12,"nctId":557,"briefTitle":558,"officialTitle":559,"acronym":560,"eligibilityCriteria":561,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":562,"targetDuration":4,"studyType":23,"phases":564,"briefSummary":565,"conditions":566,"keywords":571,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":577,"lastUpdatePostDateStruct":578,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":47},"100639253","phase-4-glp-1-agonists-for-prevention-of-recurrent-hypertriglyceridemic-acute-pancreatitis-100639253","NCT07617155","GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis","Effects of GLP-1 Agonists on Prevention of HTG-Induced Acute Pancreatitis Recurrence: Protocol for a Randomized Clinical Trial","RECAP-GLP1","Inclusion Criteria\n\n* Age ≥ 18 years old\n* Previous diagnosis of index HTG-AP (defined as AP with serum TG \\>1000 mg\u002FdL or a serum TG level of 500-1000 mg\u002FdL accompanied by chylous serum)36-38\n* Having HTG as the exclusive cause of AP\n* Time from discharge of index HTG-AP to recruitment between 4 weeks to 3 months, without AP-related symptoms between discharge and recruitment\n* Expression of the willingness to comply with lifestyle modification during the study period.\n* Clinically stable at the time of inclusion\n* The ability to understand the trial and completing it, as evaluated by the investigators.\n* Patients who may get pregnant should ensure using contraceptives for 20 months after inclusion Exclusion Criteria\n* History of malignancy in past 5 years\n* History of hypothyroidism, nephrotic syndrome, Cushing's syndrome or AIDS\n* History of chronic pancreatitis or pancreatic neoplasm\n* History of severe cardiovascular and pulmonary diseases, such as heart failure, coronary heart disease and chronic obstructive pulmonary disease.\n* Severe renal deficiency (glomerular filtration rate \\\u003C 30 ml\u002Fmin)\n* Severe hepatic deficiency (Child-Pugh Class B or C)\n* Previous pancreatic surgery\n* Recurrent AP due to pancreatic diverticulum\n* Recurrent AP due to known genetic mutations (eg. CFTR)\n* Personal or family history of medullary thyroid carcinoma (MTC)\n* Current or prior diagnosis or suspected diagnosis of multiple endocrine neoplasia type 2 (MEN2)\n* Serious hypersensitivity reaction to semaglutide or any of the excipients in the investigational drug or placebo\n* Pregnancy\n* Breast-feeding",{"count":563,"type":22},396,[276],"Hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is associated with a high risk of recurrence despite standard lipid-lowering therapy and lifestyle modification. The goal of this clinical trial is to evaluate whether GLP-1 receptor agonist therapy can reduce the recurrence of HTG-AP in adults with a history of HTG-AP and hypertriglyceridemia.\n\nThe main questions this study aims to answer are:\n\n* Whether GLP-1 receptor agonist therapy reduces the recurrence rate of HTG-AP.\n* Whether GLP-1 receptor agonist therapy improves triglyceride control, body weight, and metabolic parameters.\n* Whether GLP-1 receptor agonist therapy is safe and well tolerated in this patient population.\n\nResearchers will compare GLP-1 receptor agonist therapy plus standard care with standard care alone to determine whether GLP-1 receptor agonist therapy provides additional benefit in preventing recurrent HTG-AP.\n\nParticipants will:\n\n* Receive either GLP-1 receptor agonist therapy plus standard care or standard care alone.\n* Undergo regular clinical follow-up visits and laboratory assessments.\n* Receive monitoring of triglyceride levels, recurrence events, metabolic outcomes, and adverse events during the study period.",[567,568,569,570],"Hypertriglyceridemia Induced Acute Pancreatitis","Recurrent Acute Pancreatitis","Pancreatitis Relapsing","Hypertriglyceridemia",[572,573,574,575,576],"hypertriglyceridemia-induced acute pancreatitis","recurrent acute pancreatitis","semaglutide","GLP-1 receptor agonist","pancreatitis prevention","2026-05-28",{"date":548,"type":39},{"date":580,"type":22},"2026-09",{"date":582,"type":22},"2028-12",{"name":45,"class":46},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":4,"eligibilityCriteria":590,"healthyVolunteers":12,"sex":17,"minAge":198,"maxAge":4,"enrollmentInfo":591,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":592,"conditions":593,"keywords":594,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":600,"completionDateStruct":601,"leadSponsor":602,"locationsCount":47},"100637674","machine-learning-model-based-on-baroreflex-sensitivity-for-predicting-post-induction-hypotension-in-elderly-patients-100637674","NCT07618416","Machine Learning Model Based on Baroreflex Sensitivity for Predicting Post-Induction Hypotension in Elderly Patients","Development of a Baroreflex Sensitivity-Based Multifactorial Machine Learning Model for Predicting Post-Induction Hypotension in Elderly Patients","Inclusion Criteria:\n\n* Aged over 65 years;\n* Scheduled for elective non-cardiac surgery;\n* American Society of Anesthesiologists (ASA) physical status classification I-III;\n* Planned for general anesthesia with endotracheal intubation;\n* Patient and legal guardians are capable of understanding the study protocol and willing to provide written informed consent.\n\nExclusion Criteria:\n\n* Severe peripheral vascular diseases;\n* Secondary hypertension;\n* Presence of physical tremors (e.g., Parkinson's disease) preventing stable recording;\n* Inability to accurately measure upper limb blood pressure;\n* Pre-existing cardiac arrhythmias (e.g., atrial fibrillation) that render BRS;\n* Psychiatric disorders or cognitive impairments hindering basic cooperation.",{"count":106,"type":22},"The purpose of this study is to develop a high-performance machine learning model combining dynamic baroreflex sensitivity (BRS) metrics and multi-dimensional static clinical features to predict the risk of post-induction hypotension (PIH) in elderly patients undergoing elective non-cardiac surgery under general anesthesia.",[543],[595,546,596,597],"post-induction hypotension","baroreflex sensitivity","machine learning","2026-05-25",{"date":548,"type":39},{"date":548,"type":22},{"date":552,"type":22},{"name":45,"class":46},{"id":604,"slug":605,"hasResults":12,"nctId":606,"briefTitle":607,"officialTitle":608,"acronym":4,"eligibilityCriteria":609,"healthyVolunteers":466,"sex":329,"minAge":18,"maxAge":610,"enrollmentInfo":611,"targetDuration":4,"studyType":108,"phases":4,"briefSummary":612,"conditions":613,"keywords":615,"overallStatus":138,"whyStopped":4,"lastUpdateSubmitDate":620,"lastUpdatePostDateStruct":621,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":628},"100638913","differences-in-pelvic-floor-motion-level-among-chinese-women-and-construction-of-an-assessment-system-100638913","NCT07608146","Differences in Pelvic Floor Motion Level Among Chinese Women and Construction of an Assessment System","Differences in Pelvic Floor Movement Levels Based on Population Characteristics and the Construction of an Assessment System","Inclusion Criteria:\n\n* Female, aged between 18 and 60 years old\n* Signed the informed consent form\n* Healthy group demonstrated no pelvic floor dysfunction\n* SUI group had stress urinary incontinence symptom\n\nExclusion Criteria:\n\n* Participants with cognitive behavioral disorders, mental illnesses, or those who are unable to cooperate\n* Participants who cannot demonstrate correct pelvic floor muscle contraction\n* Participants who were within 1 year postpartum\n* Participants who were post hysterectomy\n* Participants who had pain during internal exam or refused to have internal exam\n* SUI group who had pelvic organ prolapse symptoms or whose POP-Q lowest level reached or exceeded the hymenal ring\n* SUI group had urgency urinary incontinence symptoms\n* SUI group had chronic constipation symptoms","60 Years",{"count":512,"type":22},"The purpose of this study is to integrate millimeter-wave radar technology to investigate the dynamic movement characteristics of the pelvic floor muscles in patients with different Body Mass Index (BMI) and stress urinary incontinence. Based on this, a large database of pelvic floor movement parameters for Chinese women will be constructed, and a multi-subgroup standard atlas of pelvic floor muscle movement will be established to promote the standardized application of this technology in obstetrics and gynecology clinical assessments. This study also aims to explore the clinical value of pelvic floor movement assessment within the pelvic floor evaluation system, providing directions and insights for establishing a systematic evaluation system and standardizing the diagnosis and treatment of pelvic floor disorders.",[614],"Stress Urinary Incontinence (SUI)",[616,617,618,619],"Stress urinary incontinence","Pelvic floor muscle strength","Non-invasive technology","Pelvic floor dysfunction","2026-05-24",{"date":622,"type":39},"2026-05-27",{"date":624,"type":22},"2026-05-30",{"date":626,"type":22},"2027-08-31",{"name":45,"class":46},20,""]